6-chloro-N-isobutylpyrazin-2-amine | 642459-37-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-chloro-N-isobutylpyrazin-2-amine
• 英文别名: (6-chloro-pyrazin-2-yl)-isobutyl-amine；6-chloro-N-(2-methylpropyl)pyrazin-2-amine
• CAS: 642459-37-8
• 化学式: C₈H₁₂ClN₃
• mdl: MFCD13562465
• 分子量: 185.656
• InChiKey: FECYIZSEVLCHGW-UHFFFAOYSA-N

物化性质

• 沸点：
  285.6±35.0 °C(Predicted)
• 密度：
  1.181±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为产物：
  描述：

  2,6-二氯吡嗪 、 异丁胺 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以78%的产率得到6-chloro-N-isobutylpyrazin-2-amine
  参考文献：
  名称：

  EP3239143

  摘要：

  公开号：

文献信息

• BIARYL DERIVATIVE AS GPR120 AGONIST
  申请人：LG Chem, Ltd.

  公开号：EP3239143A2

  公开（公告）日：2017-11-01

  The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

  本发明涉及一种由化学式1表示的生物芳基衍生物、生产该生物芳基衍生物的方法、包含该生物芳基衍生物的药物组合物以及该生物芳基衍生物的用途，由化学式1表示的生物芳基衍生物作为GPR120激动剂，促进胃肠道中GLP-1的生成、从巨噬细胞、胰腺细胞等的抗炎活性中降低肝脏、肌肉等的胰岛素抵抗，并可有效用于预防或治疗炎症或代谢性疾病，如糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝、脂肪肝和骨质疏松症。
• Biaryl derivative as GPR120 agonist
  申请人：LG CHEM, LTD.

  公开号：US11261186B2

  公开（公告）日：2022-03-01

  Compounds having the chemical formula 1, a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

  具有化学式1的化合物，制备所述化学式1化合物的方法，包含所述化合物的药物组合物，以及将其用作一种GPR120激动剂，用于预防或治疗炎症或代谢性疾病，如糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝病、脂肪肝病和骨质疏松症。
• VIRAL POLYMERASE INHIBITORS
  申请人：Beaulieu Pierre L.

  公开号：US20100286131A1

  公开（公告）日：2010-11-11

  Compounds of formula I: wherein, R 2 , R 5 and R 6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2004004730A2

  公开（公告）日：2004-01-15

  The invention provides a compound of the general formula (I) wherein R1 is selected from hydrogen, cycloalkyl and cycloalkenyl having 3 to 7 ring members; phenyl-C1-4 alkyl or a group R4-A-CH2-, R2 is selected from aryl and heteroaryl having five to twelve ring members; cycloalkyl and cycloalkenyl having 3 to 7 ring members; a group (CR6R7)pE-R8, or R1 and R2 together with the nitrogen atom to which they are attached form a heterocyclic group having 5 to 10 ring members; R3 is a substituent selected from halogen, CN, N-linked monocyclic nitrogen-containing heterocyclic groups having from 3 to 7 ring members and containing up to three heteroatoms; and a group Ra-Rb. The substituents R4-R, Ra and Rb are defined in claim 1. The compounds have activity as inhibitors of cyclin dependent kinases and are useful in the treatment of disease states and conditions, such as proliferative diseases, mediated by cyclin dependent kinases.